Position Paper: Are We Abandoning IQ and OQ? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Position Paper: Are We Abandoning IQ and OQ?
The author explores differences between two qualification documents, the draft guidance from FDA "Process Validation: General Principles and Practice" and the ASTM E2500-7 standard "Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment."


Pharmaceutical Technology
Volume 33, Issue 11

Conclusion

As a final thought, FDA has also moved away from statements made in the original 1987 guidance. Among these departures are:

  • In the original document, FDA discussed IQ and OQ
  • The original document contained definitions of the various validation practices such as prospective and retrospective
  • There was definite link to QA by insisting on QA procedures
  • It stressed the participation of QA in equipment design and selection
  • There was a separate section on medical device preproduction QA activities.

These are only a few of the departures but significant ones.


Table III (continued): ASTM E2500 and FDA draft guidance topic comparisons.
Over the years, the practice of validation has been truncated, revised, and reinvented. The old standby of IQ, OQ, and PQ has been criticized by some as not being in step with current technology and evolution of practices. The industry had matured, it was argued, and to such a point that everyone now understands GXP, or good X (variable) practices, including GEP. Though the industry has matured, human nature may not have. Problems of quality still occur and recalls still happen.

There was really nothing wrong with the original practice of IQ and OQ. Granted, it was in need of improvement and standardization, especially with regard to scope of activity. FDA has not abandoned the concept of qualification as pointed out in its draft guidance. To eliminate QA (QU) and rely on verification practices that have not been independently scrutinized is not correct either. The use of the SME only complicates the practice of qualification even more by requiring another individual for document approval in place of QA and to make critical decisions. The question to be asked is why the SME could not reside in and be part of QA? Because the QU was originally intended as the independent observer and reviewer, why couldn't this be the new structure?

Our present situation is complicated by the variety of non-harmonized approaches and standards. If it is not ASTM, it's the ISO. If it is not the FDA, it's the EU or Medicines and Healthcare Products Regulatory Agency (MHRA). If it is not ISPE, it's the PDA (Parenteral Drug Association). Even within the regulations, there is inconsistency of meaning and implementation. ICH Q7A and other documents discuss IQ, OQ, and PQ, but the new guideline only mentions PQ (7).

There needs to be a halt to the reinventing of qualification and validation. Yes, technology improves, and understanding and practice move forward. In the end, we still have to properly verify through qualification.

Several ideas are listed below for harmonizing the concept and practice of equipment and system qualification and process validation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here